PO.TB10.09 · 肿瘤生物学
MTAP缺失重塑胰腺导管腺癌的免疫和增殖格局
MTAP loss reshapes the immune and proliferative landscape of pancreatic ductal adenocarcinoma
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
S-甲基-5′-硫代腺苷磷酸化酶(MTAP)由位于9p21的MTAP基因编码,在癌症中常与细胞周期蛋白依赖性激酶2A(CDKN2A)一起发生纯合共缺失。因此,MTAP缺陷导致癌细胞对靶向多种通路的药物产生关键脆弱性。MTAP缺陷还被发现可预测对免疫检查点抑制剂的不良反应。胰腺导管腺癌属于MTAP缺陷率特别高的一组肿瘤。为进一步了解MTAP缺陷与非缺陷癌症之间在肿瘤微环境和增殖活性方面的潜在差异,我们采用8标志物多重免疫组织化学方法分析了一个包含378例胰腺导管腺癌的组织微阵列。就固有免疫浸润而言,与保留MTAP的肿瘤相比,MTAP缺失与显著更高密度的CD68⁺巨噬细胞相关(p = 0.010),这一效应主要由间质CD68⁺PanCK⁻巨噬细胞驱动(p = 0.005)。相比之下,总淋巴细胞密度(CD45⁺CD68⁻PanCK⁻)在MTAP缺失肿瘤中仅显示轻微的、无统计学意义的增加。然而,肿瘤区室内的增殖性淋巴细胞(CD45⁺CD68⁻MCM3⁺Ki67⁺PanCK⁺)在MTAP缺失病例中显著富集(p = 0.018),而缺乏Ki67的增殖性上皮内淋巴细胞(CD45⁺CD68⁻MCM3⁺PanCK⁺)显示出密度更高的趋势(p = 0.052)。肿瘤细胞增殖活性在MTAP缺失肿瘤中持续升高,表现为极早期(Ki67⁻MCM3⁺;p = 0.004)、早期(MCM3⁺;p = 0.007)和中期(Ki67⁺MCM3⁺;p = 0.030)细胞周期阶段标记指数的显著增加。临床病理参数进一步调节了这些关联。早期肿瘤(pT1-2)显示出比pT3-4肿瘤更高的淋巴细胞密度(p = 0.025),尤其在MTAP缺失病例中,而保留MTAP的肿瘤在pT1-2病变中显示出比pT3-4病变更高密度的增殖性巨噬细胞(p < 0.001)。淋巴结阴性肿瘤(pN0)表现出比pN⁺肿瘤更高的上皮内淋巴细胞(p = 0.044)和增殖性淋巴细胞(p = 0.036)密度,在保留MTAP的病例中最为突出。同样,较低级别肿瘤(1-2级)显示出显著更高的上皮内增殖性淋巴细胞密度(p < 0.005),相比之下3级肿瘤则较低,这同样在很大程度上局限于保留MTAP的癌症。据此得出结论,MTAP缺陷通过促进间质巨噬细胞积累以及免疫和肿瘤区室内的增殖增加,影响胰腺导管腺癌的免疫微环境。
查看英文原文 English abstract
S-methyl-5′-thioadenosine phosphorylase (MTAP) is encoded by the MTAP gene located at 9p21 and is often homozygously co-deleted in cancer together with cyclin dependent kinase 2A (CDKN2A). As a result, MTAP deficiency results in a critical vulnerability of cancer cells towards drugs targeting multiple pathways. MTAP deficiency has also been found to predict poor response to immune checkpoint inhibitors. Ductal adenocarcinoma of the pancreas belongs to a group of tumors with a particularly high rate of MTAP deficiencies. To learn more on potential differences in the tumor-microenvironment and proliferative activity between MTAP deficient and proficient cancers, a tissue microarray containing 378 pancreatic ductal adenocarcinomas were analyzed by an 8-marker multiplex immunohistochemistry approach. With respect to innate immune infiltration, MTAP loss was associated with significantly higher densities of CD68⁺ macrophages compared to MTAP-retained tumors (p = 0.010), an effect predominantly driven by stromal CD68⁺PanCK⁻ macrophages (p = 0.005). In contrast, total lymphocyte densities (CD45⁺CD68⁻PanCK⁻) showed only a mild, non-significant increase in MTAP-loss tumors. However, proliferative lymphocytes within the tumor compartment (CD45⁺CD68⁻MCM3⁺Ki67⁺PanCK⁺) were significantly enriched in MTAP-loss cases (p = 0.018), while proliferative intraepithelial lymphocytes lacking Ki67 (CD45⁺CD68⁻MCM3⁺PanCK⁺) showed a trend toward higher density (p = 0.052). Tumor cell proliferative activity was consistently elevated in MTAP-loss tumors, reflected by significantly increased labeling indices in very early (Ki67⁺MCM3⁺; p = 0.004), early (MCM3⁺; p = 0.007), and intermediate (Ki67⁺MCM3⁺; p = 0.030) cell-cycle phases. Clinicopathological parameters further modulated these associations. Early-stage tumors (pT1-2) displayed higher lymphocyte densities than pT3-4 tumors (p = 0.025), particularly in MTAP-loss cases, whereas MTAP-retained tumors showed higher densities of proliferating macrophages in pT1-2 than in pT3-4 lesions (p < 0.001). Nodal-negative tumors (pN0) exhibited higher intraepithelial lymphocyte (p = 0.044) and proliferative lymphocyte (p = 0.036) densities than pN⁺ tumors, most prominently in MTAP-retained cases. Similarly, lower-grade tumors (Grade 1-2) demonstrated significantly higher intraepithelial proliferative lymphocyte densities (p < 0.005) compared to Grade 3 tumors, again largely restricted to MTAP-retained cancers. It is concluded, that MTAP deficiency impacts the immune microenvironment of pancreatic ductal adenocarcinoma by promoting stromal macrophage accumulation and increased proliferation within immune and tumor compartments.
利益披露 Disclosure
N. F. Debatin, None..
E. Bady, None..
J. H. Müller, None..
R. Simon, None..
C. Bernreuther, None..
N. Schraps, None..
F. Gehrisch, None..
N. Gorbokon, None..
F. Viehweger, None..
F. Jacobsen, None.
G. Sauter,
MS Validated Antibodies GmbH, Hamburg, Germany Other, The recombinant rabbit monoclonal antibody: panCK (MSVA-000R), CD45 (MSVA-045R), MTAP (MSVA-741R), p53 (MSVA-053R), p16 (MSVA-016R), and the mouse monoclonal antibody Ki67 (MSVA-267M), MCM3 (MSVA-503M) were provided from MS Validated Antibodies GmbH (owned by a family member of Guido Sauter)..
K. Möller, None..
A. Lübke, None..
A. Hinsch, None..
T. S. Clauditz, None..
E. C. Burandt, None..
Z. Huang, None.